Preview Mode Links will not work in preview mode

MedEdTalks - Ophthalmology

Jul 29, 2020

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence...


Jul 29, 2020

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence...


Jul 29, 2020

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence...


Jul 29, 2020

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence...


Jul 29, 2020

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence...